http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2012233059-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebd36a4fba0ee5a478837e96cb5821ac |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 2012-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ceded7ff74e56a0b620bfcf939b5e13a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fcb3815dd5755187fab9280fd3164d9 |
| publicationDate | 2012-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2012233059-A1 |
| titleOfInvention | Compositions comprising MG29 nucleic acids, polypeptides and associated methods of use |
| abstract | Abstract Disclosed herein are compositions and methods for treatment of muscle dysfunction (including sarcopenia) and other diseases involving skeletal muscle, including age-related muscle dysfunction. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal muscle disorder, including those related to the normal aging process. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with altered intracellular Ca2+ reulgation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced. Figure 1 A Eco" P,1- pTLcG-FgMG29 v2 (10.8 kb) ....... n . ... A" A=" gem destneed EcoRI PUIProbe I Probe 2 u 1.1kb 9.7kb Previous GFP cassette Inveried GFP cassette |
| priorityDate | 2008-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 271.